The use of idiotype as a target for clinical immunotherapy of B cell malignancies.
Kim
S B
SB
Department of Experimental Transplantation and Immunology, Medicine Branch, Division of Clinical Sciences, NCI, Frederick, MD 21702, USA.
Kwak
L W
LW
D000276:Adjuvants, Immunologic; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D016233:Immunotherapy, Active; D016393:Lymphoma, B-Cell / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes